Uncategorized
Human embryonic stem cell-derived RPE cell transplantation yields no ‘untoward pathologic reactions’
MIAMI — A study under way to evaluate safety and tolerability of subretinal transplantation of human embryonic stem cells in patients with dry age-related macular degeneration so far has yielded no “untoward pathologic reactions,” a speaker said here. “Human embryonic stem cells are a robust renewable source of terminally differentiated, young, healthy [retinal pigment epithelium] cells,” Ninel Z. Gregori, MD, told colleagues at the Angiogenesis, Exudation, and Degeneration 20014 meeting. “This is the first clinical trial transplanting hESC-derived RPE cells into human patients.”